Cat. No.: DAB-0012901
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Hamster, Monkey |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu100 of human thioredoxin 2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TXN2 |
| UniProt No. | Q99757 |
| Gene ID | 25828 |
| Gene Description | Thioredoxin is a small redox protein found in many eukaryotes and prokaryotes. A pair of cysteines within a highly conserved, active site sequence can be oxidized to form a disulfide bond that is then reduced by thioredoxin reductase. Multiple forms of thioredoxin have been identified, including cytosolic thioredoxin 1 and mitochondrial thioredoxin 2. Thioredoxin participates in many cellular processes including redox signaling, response to oxidative stress, and protein reduction. A potential role of thioredoxin in human disorders such as cancer, aging, and heart disease is currently under investigation. Thioredoxin can play a key role in cancer progression, because it acts as a negative regulator of the proapoptotic kinase ASK1. Changes in thioredoxin expression have been associated with meningococcal septic shock and acute lung injury. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
